Merck completed the acquisition of Modifi Biosciences for $1.3bn.

Merck, a science and technology company, completed the acquisition of Modifi Biosciences, a preclinical stage biotechnology company, for $1.3bn. “In founding Modifi Biosciences, we sought to radically change the oncology treatment paradigm for cancer patients with glioblastoma and other tumors. We are honored to have Merck recognize the potential of our science, and as an oncology company, they are perfectly positioned to advance our innovations through clinical trials and commercialization," Ranjit S. Bindra, Modifi Biosciences Co-founder, Harvey and Kate Cushing, Professor of Therapeutic Radiology at Yale School of Medicine, and Scientific Director of the Yale Brain Tumor Center at Smilow Cancer Hospital.